{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:19:51Z","timestamp":1790709591377,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Travel Medicine and Infectious Disease"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.tmaid.2022.102267","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T12:45:27Z","timestamp":1643114727000},"page":"102267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models"],"prefix":"10.1016","volume":"46","author":[{"given":"Li-li","family":"zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa-ming","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-yun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-xiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-bin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4491-9281","authenticated-orcid":false,"given":"Jing-shuang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"982","key":"10.1016\/j.tmaid.2022.102267_bib1","first-page":"1","article-title":"WHO expert consultation on rabies. Second report","author":"World Health","year":"2013","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"9951","key":"10.1016\/j.tmaid.2022.102267_bib2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(13)62707-5","article-title":"Current status of rabies and prospects for elimination","volume":"384","author":"Fooks","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102267_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003709","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Neglected Trop Dis"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102267_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003709","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.tmaid.2022.102267_bib5","unstructured":"Overview of the national epidemic situation of notifiable infectious diseases in China in 2020. Available online:https:\/\/www.cn-healthcare.com\/article\/20210312\/content-552221.html."},{"issue":"1","key":"10.1016\/j.tmaid.2022.102267_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3201\/eid1301.060810","article-title":"Rabies encephalitis in malaria-endemic area, Malawi, Africa","volume":"13","author":"Macpherson","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tmaid.2022.102267_bib7","series-title":"Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline","author":"Sparrow","year":"2019"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102267_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s11908-009-0044-0","article-title":"Update on rabies diagnosis and treatment","volume":"11","author":"Jackson","year":"2009","journal-title":"Curr Infect Dis Rep"},{"issue":"11","key":"10.1016\/j.tmaid.2022.102267_bib9","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1371\/journal.pntd.0000542","article-title":"Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans","volume":"3","author":"M\u00fcller","year":"2009","journal-title":"PLoS Neglected Trop Dis"},{"issue":"14","key":"10.1016\/j.tmaid.2022.102267_bib10","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants","volume":"79","author":"Bakker","year":"2005","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.tmaid.2022.102267_bib11","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","article-title":"Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates","volume":"25","author":"Sloan","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.tmaid.2022.102267_bib12","first-page":"1","article-title":"Monoclonal antibodies for the prevention of rabies: theory and clinical practice","author":"Nagarajan","year":"2014","journal-title":"Antib Technol J"},{"issue":"6","key":"10.1016\/j.tmaid.2022.102267_bib13","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1128\/jvi.64.6.3087-3090.1990","article-title":"Biological characterization of human monoclonal antibodies to rabies virus","volume":"64","author":"Dietzschold","year":"1990","journal-title":"J Virol"},{"issue":"1\u20132","key":"10.1016\/j.tmaid.2022.102267_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-1759(99)00223-9","article-title":"The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure","volume":"235","author":"Champion","year":"2000","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.tmaid.2022.102267_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/375247","article-title":"Development of a cocktail of recombinant-expressed human rabies virus--neutralizing monoclonal antibodies for postexposure prophylaxis of rabies","volume":"188","author":"Prosniak","year":"2003","journal-title":"JID (J Infect Dis)"},{"issue":"8","key":"10.1016\/j.tmaid.2022.102267_bib16","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1128\/JVI.79.8.4672-4678.2005","article-title":"Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis","volume":"79","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.tmaid.2022.102267_bib17","first-page":"67","article-title":"Human monoclonal antibody and vaccine approaches to prevent human rabies","volume":"317","author":"Nagarajan","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102267_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.antiviral.2011.06.002","article-title":"G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates","volume":"91","author":"Wang","year":"2011","journal-title":"Antivir Res"},{"issue":"50","key":"10.1016\/j.tmaid.2022.102267_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2012.09.027","article-title":"Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults","volume":"30","author":"Gogtay","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102267_bib20","doi-asserted-by":"crossref","DOI":"10.4172\/jaa.1000061","article-title":"Conservation of binding epitopes for Monoclonal Antibodies on the rabies virus glycoprotein","volume":"5","author":"Kuzmina","year":"2013","journal-title":"J Antivir Antiretrovir"},{"issue":"3","key":"10.1016\/j.tmaid.2022.102267_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: a phase 2\/3, randomized, single-blind, noninferiority, controlled study","volume":"66","author":"Gogtay","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.tmaid.2022.102267_bib22","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/500470","article-title":"Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin","volume":"193","year":"2006","journal-title":"JID (J Infect Dis)"},{"issue":"49","key":"10.1016\/j.tmaid.2022.102267_bib23","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1016\/j.vaccine.2013.09.038","article-title":"Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment","volume":"31","author":"Papaneri","year":"2013","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.tmaid.2022.102267_bib24","doi-asserted-by":"crossref","first-page":"e0006133","DOI":"10.1371\/journal.pntd.0006133","article-title":"SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies","volume":"11","author":"Chao","year":"2017","journal-title":"PLoS Neglected Trop Dis"},{"issue":"1","key":"10.1016\/j.tmaid.2022.102267_bib25","article-title":"In vivo efficacy of SYN023, an anti-rabies monoclonal antibody cocktail, in post-exposure prophylaxis Animal models","volume":"5","author":"Chao","year":"2020","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.tmaid.2022.102267_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104956","article-title":"Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects","volume":"184","author":"Ding","year":"2020","journal-title":"Antivir Res"},{"issue":"7","key":"10.1016\/j.tmaid.2022.102267_bib27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cpdd.917","article-title":"Safety, pharmacokinetics, and neutralizing activity of SYN023, a mixture of two novel antirabies monoclonal antibodies intended for use in postrabies exposure prophylaxis","volume":"10","author":"McClain","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1016\/j.tmaid.2022.102267_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: a phase 2\/3, randomized, single-blind, noninferiority, controlled study","volume":"66","author":"Gogtay","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmaid.2022.102267_bib29","unstructured":"Qian Jia,. et al,. Development of a novel recombinant human anti-rabies monoclonal antibody NM57.China patent NO.CN101100663B."},{"key":"10.1016\/j.tmaid.2022.102267_bib30","unstructured":"Craig Hooper Douglas and Bernhard Dietzschold, Recombinant antibodies, and compositions and methods for making and using the same, China patent CN1636019B."},{"issue":"4","key":"10.1016\/j.tmaid.2022.102267_bib31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1006\/biol.1998.0162","article-title":"A comparison of two serological methods for detecting the immune response after rabies vaccination in dogs and cats being exported to rabies-free areas","volume":"26","author":"Briggs","year":"1998","journal-title":"Biologicals"},{"key":"10.1016\/j.tmaid.2022.102267_bib32","first-page":"1","article-title":"Laboratory techniques in rabies","volume":"23","author":"D'Antona","year":"1954","journal-title":"Monogr Ser World Health Organ"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102267_bib33","first-page":"519","article-title":"Animal rabies in the People's Republic of China","volume":"37","author":"Feng","year":"2018","journal-title":"Revue scientifique et technique (International Office of Epizootics)"},{"issue":"1","key":"10.1016\/j.tmaid.2022.102267_bib34","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1186\/s12913-019-4730-9","article-title":"Analyzing the distribution of rabies clinics and achievements of standardized rabies clinics implementation in mainland China","volume":"19","author":"Du","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.tmaid.2022.102267_bib35","first-page":"P33","article-title":"Characteristics of rabies street virus strain BD06 for challenge test in dogs","volume":"27","author":"Liu","year":"2014","journal-title":"Chin.J Biologicals."},{"key":"10.1016\/j.tmaid.2022.102267_bib36","first-page":"103","article-title":"Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 3","volume":"25","author":"Atanasiu","year":"1961","journal-title":"Bull World Health Organ"},{"issue":"37","key":"10.1016\/j.tmaid.2022.102267_bib37","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","article-title":"Rabies vaccines: WHO position paper, April 2018 - Recommendations","volume":"36","author":"Organization","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102267_bib38","doi-asserted-by":"crossref","first-page":"e0003502","DOI":"10.1371\/journal.pntd.0003502","article-title":"The spatiotemporal expansion of human rabies and its probable explanation in mainland China, 2004-2013","volume":"9","author":"Yao","year":"2015","journal-title":"PLoS Neglected Trop Dis"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102267_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.15252\/emmm.201505986","article-title":"Development of broad\u2010spectrum human monoclonal antibodies for rabies post\u2010exposure prophylaxis","volume":"8","author":"De Benedictis","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102267_bib40","first-page":"593","article-title":"Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons: Part II*","volume":"14","author":"Atanasiu","year":"1956","journal-title":"Bull World Health Organ"},{"issue":"3","key":"10.1016\/j.tmaid.2022.102267_bib41","first-page":"361","article-title":"Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 4","volume":"36","author":"Atanasiu","year":"1967","journal-title":"Bull World Health Organ"},{"issue":"6","key":"10.1016\/j.tmaid.2022.102267_bib42","first-page":"747","article-title":"Inhibitory effect of passive antibody on active immunity induced against rabies by vaccination","volume":"45","author":"Wiktor","year":"1971","journal-title":"Bull World Health Organ"},{"issue":"9","key":"10.1016\/j.tmaid.2022.102267_bib43","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2307\/4593681","article-title":"Human rabies immune globulin","volume":"84","author":"Sikes","year":"1969","journal-title":"Publ Health Rep"},{"issue":"3","key":"10.1016\/j.tmaid.2022.102267_bib44","first-page":"303","article-title":"Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects","volume":"45","author":"Cabasso","year":"1971","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.tmaid.2022.102267_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-1157(74)80007-7","article-title":"Properties of rabies immune globulin of human origin","volume":"2","author":"Cabasso","year":"1974","journal-title":"J Biol Stand"},{"issue":"3","key":"10.1016\/j.tmaid.2022.102267_bib46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1128\/am.27.3.553-561.1974","article-title":"Antibody response to a human diploid cell rabies vaccine","volume":"27","author":"Cabasso","year":"1974","journal-title":"Appl Microbiol"},{"issue":"3","key":"10.1016\/j.tmaid.2022.102267_bib47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0264-410X(88)90225-3","article-title":"Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment","volume":"6","author":"Vodopija","year":"1988","journal-title":"Vaccine"}],"container-title":["Travel Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893922000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893922000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:06:42Z","timestamp":1761487602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477893922000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":47,"alternative-id":["S1477893922000138"],"URL":"https:\/\/doi.org\/10.1016\/j.tmaid.2022.102267","relation":{},"ISSN":["1477-8939"],"issn-type":[{"value":"1477-8939","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models","name":"articletitle","label":"Article Title"},{"value":"Travel Medicine and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmaid.2022.102267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102267"}}